Loading...

Custom Cancer Insurance And Digital Underwriting Will Drive Future Expansion

Published
06 Aug 24
Updated
04 Oct 25
AnalystConsensusTarget's Fair Value
US$108.31
2.6% overvalued intrinsic discount
04 Oct
US$111.17
Loading
1Y
-0.4%
7D
0.5%

Author's Valuation

US$108.312.6% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on04 Oct 25
Fair value Increased 0.21%

Aflac's analyst price target has been raised slightly, with an increase of $2 to $108. Analysts highlight strong Q2 sales driven by new product rollouts and improved net interest income.

Shared on07 May 25
Fair value Increased 11%

Shared on30 Apr 25
Fair value Increased 2.28%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on23 Apr 25
Fair value Increased 0.042%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 0.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.89%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 9.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 2.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 9.54%